Shares of heart disease concern Cytokinetics, Incorporated (NASDAQ:CYTK) continued to be whipsawed by off and on-again buyout speculation. This week it was speculated that Eli Lilly (LLY) might be an interested party. Novartis (NVS), Johnson & Johnson (JNJ), Amgen (AMGN) and AstraZeneca (AZN) have all been linked at one time as potential suitors for this midcap concern in recent months. This most recent buyout chatter came two weeks after the CEO at Cytokinetics stated the company was perfectly comfortable remaining a standalone entity, which took some wind out of the sales of the stock.